POC Diagnostics in 2025: What the Market Got Right and What's Still Broken
POC Diagnostics in 2025: What the Market Got Right and What's Still Broken
Point-of-care diagnostics had a good year. Funding rounds closed, FDA clearances landed, and the phrase "decentralized testing" stopped sounding like a pitch deck buzzword and started sounding like an operating assumption. But spend enough time in this industry and you start to notice a gap between the narrative and the lab bench. The market got a lot right in 2025. It also built up some habits that are going to slow it down if nobody says so out loud.
What the Market Got Right
Start with the obvious: the shift toward decentralization is real, and it's not slowing down. Testing that used to require a courier, a centralized lab, and a 48-hour turnaround is increasingly happening where the patient, the farmer, or the field technician already is. That's not a trend chasing convenience for its own sake — it's a recognition that the value of a diagnostic result decays the longer you wait for it. A glucose reading three days late isn't a diagnostic. It's a historical record.
The industry also got smarter about who its actual customer is. A few years ago, "point of care" mostly meant hospital point of care — nurses, urgent care clinics, the occasional ambulance. In 2025, the addressable market expanded into spaces that don't look anything like a clinic: veterinary practices, agricultural operations, environmental monitoring, direct-to-consumer wellness. That expansion forced companies to think about cost, usability, and deployment in ways that hospital-grade equipment never had to. A $30,000 benchtop analyzer is a non-starter for a dairy farm. That constraint, uncomfortable as it's been for legacy players, has pushed real innovation.
And capital followed the signal. Investors who spent the early 2020s skeptical of diagnostics — burned by COVID-era boom-and-bust cycles — came back in 2025 with a more disciplined thesis: back platforms, not single-assay products. A company that can only run one test is a product. A company that can run twenty is infrastructure. That distinction shaped where the money went, and it was the right distinction to make.
What's Still Broken
Here's the uncomfortable part. For all that progress, the industry is still building diagnostics the way it built them a decade ago: around hardware. Walk the floor at any major diagnostics conference and count how many companies are still selling a proprietary reader alongside their test. The number hasn't moved nearly as much as it should have, given how good smartphone cameras and computational color correction have gotten.
This isn't a minor architectural detail. It's the single biggest reason decentralized testing hasn't decentralized as fast as it should. Every dollar a company spends subsidizing a reader, every supply chain dependency on a hardware vendor, every support ticket about a broken scanner — all of that is friction that didn't need to exist. The hardware-first mindset made sense when phone cameras were unreliable and on-device processing was a joke. It stopped making sense around the time smartphones got good enough to outperform a lot of dedicated readers. Most of the industry just hasn't caught up to that fact yet.
The second broken piece is interoperability, or the lack of it. Platforms that should be talking to each other — assay development tools, results databases, EMR systems, agricultural management software — mostly aren't. Every company built its own walled garden, and now the industry is having the same conversation healthcare IT had fifteen years ago about EMR interoperability, except with diagnostics data. That's a solvable problem. It's just not being solved with any urgency, because no single company benefits enough from solving it alone to justify the engineering lift.
The third gap is regulatory clarity for AI-assisted result interpretation. Plenty of companies are now using machine learning to read test results, correct for ambient lighting, or flag ambiguous readings. Almost none of them have a clean answer for how that fits into the existing regulatory framework, because the framework wasn't built with this use case in mind. That ambiguity isn't stopping companies from shipping product — it's just creating a pile of regulatory risk that's going to come due eventually, for somebody.
What 2026 Needs to Look Like
The platforms that win the next phase of this market won't be the ones with the most sophisticated single test. They'll be the ones that treat hardware dependency as a liability instead of a feature, that build for interoperability instead of lock-in, and that get ahead of the regulatory questions instead of hoping nobody asks them too loudly. The market proved in 2025 that decentralization is the direction. The job now is closing the gap between that direction and how diagnostics are actually built.
